2024
(333) TRENDS IN PHOSPHODIESTERASE TYPE 5 INHIBITOR PRESCRIPTIONS AND COST: MEDICARE ANALYSIS 2017-2021
Cahill E, Reddy S, Rotker K, Honig S. (333) TRENDS IN PHOSPHODIESTERASE TYPE 5 INHIBITOR PRESCRIPTIONS AND COST: MEDICARE ANALYSIS 2017-2021. The Journal Of Sexual Medicine 2024, 21: qdae167.321. DOI: 10.1093/jsxmed/qdae167.321.Peer-Reviewed Original ResearchPhosphodiesterase type 5Non-urologistsPDE5 inhibitorsPhosphodiesterase type 5 inhibitorsMedicare Part D databaseMedicare Part D Public Use FilesCompared urologistsPrescribed tadalafilPrescribed sildenafilSildenafil prescriptionsCost of medicationsErectile dysfunctionInhibitor medicationPrescribing patternsUrologistsPatient comfortPrimary care providersSildenafilTadalafilType 5
2018
What's Gender Got to Do With It: Difference in the Proportion of Traditionally Female Cases Performed by General Urologists of Each Gender
Rotker K, Iosifescu S, Baird G, Thavaseelan S, Hwang K. What's Gender Got to Do With It: Difference in the Proportion of Traditionally Female Cases Performed by General Urologists of Each Gender. Urology 2018, 116: 35-40. PMID: 29550347, DOI: 10.1016/j.urology.2017.12.040.Peer-Reviewed Original ResearchMeSH KeywordsCareer ChoiceCatchment Area, HealthCertificationFemaleGender IdentityGynecologic Surgical ProceduresHumansLogistic ModelsMalePatient PreferencePhysicians, WomenPopulation DensityPractice Patterns, Physicians'Referral and ConsultationUnited StatesUrologic Surgical ProceduresUrologistsUrologyConceptsGeneral urologistsTotal casesCPT codesCurrent Procedural Terminology codesLogistic regression analysis modelProcedural Terminology codesCase log dataPatient populationUrogynecologic proceduresPractice patternsFemale casesTerminology codesUrologistsRegression analysis modelSignificant differencesGreater percentageAmerican BoardCertification periodUnproven hypothesisPercentageGenderMale counterpartsCases